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NMD can be recommended when eight sub-scales are used and reported. The
suggestion that the SF-36 can be utilized as a two-sub-scale measure of physical
health and mental health components in this clinical group, however, was not
supported because of model fit limitations.
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OBJECTIVES: Quality of life (QoL) is an important psychological dimension in pa-
tients with Parkinson’s disease (PD). The factor structure of the SF-36 in patients
with PD was investigated to determine how this measure might best be used to
assess QoL in this clinical population. METHODS: Confirmatory factor analyses
were conducted on self-report SF-36 data from 339 individuals diagnosed with PD.
Six structural models of the SF-36 were evaluated against data. RESULTS: The
underlying factor structure of the SF-36 in PDwas found to be inconsistentwith the
assumedmeasurement model of SF-36 but consistent with contemporary theoret-
ical models of the instrument. CONCLUSIONS: The use of the SF-36 in individuals
with PD can be recommendedwhen eight subscales are used and reported. The use
of the instrument as a two-subscale measure of physical health andmental health
components, however, was not found.
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OBJECTIVES:The purpose of this studywas to investigate changes in health related
quality of life (HRQOL) experienced by patients with multiple sclerosis (MS) and to
determine their experiences, opinions, and expectations related to disease modi-
fying drugs (DMDs) used in MS. METHODS: A sample of 18 individuals with con-
firmed diagnosis of MS was recruited through a university hospital-based neurol-
ogy clinic. Four focus group (FG) sessions involving semi-structured interviews
were conducted. The FG discussions were audio-recorded and were later tran-
scribed for coding purpose. Qualitative content analysis of transcribed data was
performed by two blinded reviewers using QSR NVivo 8 software. The data were
coded into specific themes as per the research questions. RESULTS: Qualitative
analysis indicated twelve major themes related to HRQOL associated with the dis-
ease condition and experiences with the DMDs used to treat MS: (1) HRQOL before
the diagnosis of MS; (2) HRQOL after the diagnosis of MS; (3) Coping with MS; (4)
Opinions regarding the current DMDs; (5) Clinical benefits; (6) Adverse events as-
sociated with the DMDs; (7) Side effects associated with DMDs; (8) Treatment ad-
herence; (9) Convenience of DMD administration; (10) Treatment satisfaction; (11)
Expectations from the future DMDs; and (12) Cost associatedwith DMDs. HRQOL in
social, physical, and psychological domains declined considerably among all par-
ticipants since the diagnosis of MS. Participants were content with clinical benefits
associated with DMDs they were currently taking. Future DMDs were expected to
be safer and easier to administer. CONCLUSIONS: This study provides an in-depth
understanding of the various factors that affect HRQOL of patients living with MS
and the characteristics of DMDs that are ofmost value toMS patients. Study results
support the need to determine patient preferences for specific adverse events as-
sociated with DMDs against the clinical benefits in order to improve adherence
with DMDs and consequent outcomes.
Neurological Disorders – Health Care Use & Policy Studies
PND51
THE EFFECT OF THE MEDICARE PART D COVERAGE GAP AND OUT-OF-POCKET
BURDEN ON THE USE OF DISEASE MODIFYING DRUGS TO TREAT MULTIPLE
SCLEROSIS
Banahan BFI1, Datar M1, Mendonca CM1, Shahpurwala Z1, Bentley JP1, Phillips AL2,
Stewart M3
1University of Mississippi, University, MS, USA, 2EMD Serono, Inc., Rockland, MA, USA, 3Pfizer,
Inc., New London, CT, USA
OBJECTIVES: To assess the impact of the Medicare Part D coverage gap and co-pay
levels on medication utilization behaviors among beneficiaries taking disease
modifying drugs (DMDs) for the treatment of multiple sclerosis (MS).METHODS: A
retrospective cohort study was conducted using a 5% national sample of Medicare
beneficiaries for 2007. Ambulatory patients diagnosed with MS and taking at least
one DMD were included. Adherence was measured using proportion of days cov-
ered (PDC). Patients were classified as discontinuing therapy if last day of posses-
sion was more than 60 days before the end of the year. Low income subsidy (LIS)
status was used as a measure of out-of-pocket burden. RESULTS: 1,439 beneficia-
ries with MS and DMD use were identified. 89% reached the coverage gap and 81%
reached catastrophic coverage. Average time in gap was 2 to 4 months for the
different copay groups. Overall PDC measures were 85.7% pre-gap, 81.7% during
gap, and 87.3% in catastrophic coverage. PDC for full year was higher (p0.001) for
no-copay LIS (90.2%) than for reduced-copay LIS (83.7%) and full-copay (79.8%)
beneficiaries. Full-copay beneficiaries were slightly more likely to stop therapy
after hitting the gap than were reduced-copay or no-copay beneficiaries (17.7%,
15.0%, 10.6%). Full-copay beneficiaries were more likely (p0.001) than reduced-
copay or no-copay beneficiaries to have a drop in PDC during the coverage gap
(46.3%, 28.2%, 18.1%). CONCLUSIONS:Most beneficiaries with MS reach the cover-
age gap early in the year and fairly quickly move to catastrophic coverage. Average
time in the coverage gap is limited, but significantly reduces adherence. Higher
out-of-pocket burden is also associated with a reduction in adherence.
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OBJECTIVES: Once-daily armodafinil significantly improves wakefulness in pa-
tients with excessive sleepiness due to shift work disorder (SWD), treated obstruc-
tive sleep apnea (OSA), or narcolepsy. The objective of the current analysis was to
examine resource utilization by patients who received armodafinil for these FDA-
approved indications.METHODS: Data were collected from the IMS LifeLink Data-
base (December 2008 to March 2010) and contained longitudinal patient data from
medical claims (diagnostic/therapeutic services), pharmacy claims (prescriptions),
and eligibility files (demographics and enrollment). Patients were identified and
healthcare utilization data were collected for 6months before and up to 10months
after their first armodafinil pharmacy claim. Healthcare costs and visits before and
after initiation of armodafinil were statistically analyzed using paired t-tests.
RESULTS: 1,282 patients were included (4.5% SWD; 85.9% OSA; 20.4% narcolepsy).
The mean monthly healthcare cost for patients prior to taking armodafinil was
$1,562.99 (pharmacy $432.26; medical $1,130.73). After armodafinil initiation, over-
all monthly cost decreased to $1,438.11 (p0.0588). Armodafinil significantly in-
creased prescription costs by $138.53/month (p0.0001) but decreased medical
costs by $263.41/month (p0.0001). Medical costs were decreased by $133.23 for
physician costs (p0.0001) and $75.62 for outpatient costs (p0.0039). Emergency
room costs were lower by $3.99/month (NS), and inpatient costs were lower by
$7.51/month (NS). The number of inpatient visits were reduced by 0.21/year
(p0.0307), physician visits by 4.91/year (p0.0001), and outpatient visits by 0.89/
year (p0.0001). CONCLUSIONS: After armodafinil treatment, reductions were
seen in healthcare utilization and costs compared to the pre-armodafinil period. As
expected, total prescription costs were greater following initiation of armodafinil
therapy; however, lower total monthly costs were observed with armodafinil be-
cause use of medical resources decreased. This significant reduction in medical
resource utilization appeared to be driven predominantly by fewer physician visits
and lower outpatient costs. This research was sponsored by and conducted in
collaboration with Cephalon, Inc., Frazer, PA.
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OBJECTIVES: Uncontrolled epilepsy is associated with devastating injuries, neuro-
psychiatric impairment, and increased mortality based on clinical observations.
The purpose of this study is to evaluate the clinical and economic burden of un-
controlled epilepsy in a Medicaid population. METHODS: Medical and pharmacy
claims from Florida (1997Q3-2008Q2), Iowa (1998Q1-2006Q2), Kansas (2001Q1-
2009Q2), Missouri (1997Q1-2008Q2), and New Jersey (1997Q1-2008Q4) Medicaid da-
tabaseswere analyzed. Patients18 yearswith epilepsy and receiving antiepileptic
drugs (AEDs) were selected. A retrospective matched-cohort design was used to
classify patients intomutually-exclusive cohorts of “uncontrolled” (2 consecutive
AED changes followed by 1 epilepsy-related inpatient/ER visit), “well-controlled”
(no AED change and no epilepsy-related inpatient/ER visit) and “intermediate”
(neither “uncontrolled” nor “well-controlled”) epilepsy. Patients with uncontrolled
epilepsy were matched 1:1 with those with well-controlled and intermediate epi-
lepsy, respectively, using propensity score matching. Matched cohorts were com-
pared for health care resource utilization, occurrence of negative clinical events,
and direct health care costs. Statistical differences between cohorts were assessed
using multivariate conditional regression models, adjusted for demographics,
treatment characteristics, and comorbidities. RESULTS:Uncontrolled epilepsywas
associated with significantly higher health care resource utilization (adjusted rate
ratios [ARRs] [95% confidence intervals (95%CIs)]: hospitalizations6.65 [6.41-6.90],
length of hospital stays7.72 [7.60-7.84], emergency-room visits3.67 [3.61-3.74],
outpatient visits3.85 [3.77-3.93]) versus well-controlled epilepsy. Morbidity oc-
curred more frequently in the uncontrolled group (ARRs: fractures: 2.16 [2.07-2.26],
motor vehicle accident-related injuries: 2.45 [1.77-3.40], head injuries: 2.09 [2.04-
2.14], status epilepticus events: 9.71 [8.20-11.50]) relative to well-controlled pa-
tients. Patients with uncontrolled epilepsy also incurred higher health care costs
(adjusted cost difference [95%CI]$12,258 [$10,482-$14,083] per patient per year), of
which hospitalization costs represented 46.3%. Results were similar when com-
pared to intermediate epilepsy. CONCLUSIONS: Uncontrolled epilepsy was associ-
atedwith significantly greater health care resource utilization, higher rates ofmor-
bidity, and higher medical costs compared to well-controlled and intermediate
epilepsy.
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OBJECTIVES: Identify the frequency, severity, and cost of relapses among a multi-
ple sclerosis (MS) population. METHODS: Data was assessed from MarketScan®
Research Database. Patients at least 18 years old with MS, defined at least 2 outpa-
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tient diagnostic codes forMS (ICD-9-CM 340) or one inpatient code during the index
period (1/1/2004-6/30/2008) were included. Continuous enrollment required 6 mos
pre-index and 12mos post-index. A sub-group of newly treated patients, defined as
MS patients free of DMT claims for 6 mos prior to initial MS diagnosis, were also
analyzed for frequencies of relapses. Using a claims-based definition, severe re-
lapses were defined as an inpatient hospitalizationwith a primary diagnosis of MS.
Moderate relapses were defined as an outpatient visit with a diagnosis of MS in
combination with a pharmacy or medical claim for a corticosteroid within 7 days
following the outpatient visit. Additional data collected included relapse-related
costs and length of inpatient stay. All variables were analyzed descriptively.
RESULTS: Among the 23,503 MS patients identified, mean age was 47 years and
18,027 (77%) were female. Overall, 1,479 (6.3%) patients had a relapse. 940 patients
(4.0%) had a severe relapse, with an average length of inpatient stay of 5.6 days.
Among, the sub group of newly treatedMSpatients (NTMS) (N 15,059), 1,059 (7.0%)
were classified as having a relapse, 710 (4.7%) were severe. Mean cost of relapse
[NTMS] was $12,558 [$11,485] for severe, and $1,561 [$1,844] for moderate.
CONCLUSIONS: This descriptive analysis provides an updated estimate of the fre-
quency and direct medical costs of both severe and moderate relapses among
multiple sclerosis patients. The ranges of health care services used to manage a
relapse reflect severity level. Further database analyses evaluating the impact of
disease modifying treatment on the rates and costs of relapses is warranted.
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OBJECTIVES: With inter- and intra-patient variation in cost and health resource
utilization, standard approaches to defining an episode of care (EOC) may perform
poorly. This study takes into account such variation and uses time-to-event anal-
ysis within an EOC framework to examine length and cost of care for vaso-occlu-
sive crisis (VOC) in sickle cell disease (SCD).METHODS: Florida Medicaid adminis-
trative data from 2001-2005 were used to examine EOCs. Enrollees under the age of
65 with 1 inpatient or 2 outpatient claims 30 days apart containing a primary
diagnosis of SCD (ICD-9 282.xx) and 6 months of continuous eligibility were in-
cluded in the study. Episodes began with the first VOC-related claim. Parametric
survival analysis was used to calculate episode length as the number of days by
which adjudicated payments returned to each patient’s pre-diagnosis average
charge. Episode costs were calculated as the difference between pre- and post-
diagnosis payments. EOCswere calculated by subgroups according to age (pediatric
and adult), gender, and presence of significant co-morbidity. RESULTS: Among
2,543 individuals included in the study, mean age was 14.4 years (standard devia-
tion [SD]11.9) and 48.2% were male. Mean episode length was 11.6 days (95%
confidence interval [CI]: 10.9-12.3). Pediatric patients had shorter episodes com-
pared to adults (10.5 versus 16.4 days, respectively), but there were no differences
by gender. The presence of acute chest syndrome secondary to VOC increased
episode length to 13.4 days. The incremental cost of VOC was $327 (95% CI: $310-
$343). Costs were slightly higher for males versus females and for adults versus
pediatric patients. CONCLUSIONS: Episode length as determined by parametric
survival analysiswas consistentwith the clinical presentation of VOC. Our analysis
suggests that cost may vary among patient groups with similar episode length.
Future work aims to quantify differences between standard and parameteric-
based EOC approaches.
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OBJECTIVES: Parkinson’s disease (PD) is a degenerative brain disorder of adult
onset that impairs motor function. As PD progresses, patients experience reduc-
tions in physical functioning and overall quality of life. Deep brain stimulation
(DBS) is an implantedmedical device that delivers electrical stimulation to specific
area(s) of the brain that control movement and muscle functioning. DBS has been
shown in clinical trials to significantly improve motor functioning, reduce disabil-
ity and improve the quality of life in patients and caregivers of PD patients. The
objective of this study is to compare the healthcare utilization and costs of PD
patients receivingDBS versusmedicallymanagement.METHODS: Patientswith PD
between 2006 and 2008 were identified the MarketScan Commercial Claims and
Encounters database. PD patients were segmented into medically managed pa-
tients and deep brain stimulation (DBS) patients. Medically managed PD patients
were required to be on at least one anti-parkinsonian medication. DBS patients
were identified using surgical procedure codes for lead implantation; an indexed
look-back period was used to ensure DBS patients were newly implanted. All pa-
tients were followed for one year. Annual healthcare utilization and per patient
healthcare costs were compared. RESULTS: We found that DBS patients had sig-
nificantly fewer inpatient hospitalizations (1.6 v. 2.4) and shorter lengths of stay
(2.8 v. 6.2) compared to medically managed PD patients (p 0.01). However, DBS
patients had significantly higher inpatient costs, resulting from the costs associ-
ated with DBS implantation. DBS patients had significantly lower annual pharma-
ceutical costs than PD patients ($7,105 v $11,735). The differences may be underes-
timated as DBS patients typically have more advanced PD than medically
managed. CONCLUSIONS: Our results demonstrate that medically managed PD
patients accrued significantly higher pharmaceutical costs and inpatient hospital-
ization stays compared to DBS patients. These results suggest DBS patients may
require fewer medications to manage PD symptoms.
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OBJECTIVES: This study aims to describe temporal trends and geographic discrep-
ancies on public pharmaceutical expenditures with multiple sclerosis (MS) treat-
ment in Brazil.METHODS: Longitudinal analysis of Brazilian MS pharmacy claims
as reported in the Brazilian Ambulatory Information System Database. Analyses
were based on aggregate data from the 27 Brazilian states, observed annually for
the period 2006–2009. The total MS-related expenditures were segmented by state,
drug (Glatiramer 20mg, Betainterferon 22mcg, Betainterferon 44mcg, Betainter-
feron 30 mcg, and Betainterferon 300mcg), and year. Per capita calculations were
also performed using Brazilian 2009 population. RESULTS:MS public expenditures
withMSdrugs had a significant rising from30,423,930BRL in 2006 to 214,405,349BRL
in 2009, a more than 7-fold increasing. Total investments in MS drugs totaled
629,917,685BRL. Federal funding transfers for the state of Roraima presented the
highest growth rate (1,497%) rising from 10,549BRL in 2006 to 157,973BRL in 2009.
São Paulo (41,384,039 inhabitants, 1/5 of Brazilian population) was responsible for
the higher absolute investment (13,130,526BRL and 88,948,997BRL in 2006 and 2009,
respectively) and the higher total expenditure for the period (259,591,564BRL, 1/3 of
national expenditures). The lowest spending was observed for states in the North
Region – Amapá had any MS claim in the 4-year period and Acre had the lowest
value (184,754BRL). Both states had similar projected 2009 population and are lo-
cated at regions with very similar characteristics (both ethnically and geographi-
cally). Betainterferon 44mcg represented the highest expenditures in 2009 and had
the highest annual cost per patient (54,288BRL). Conversely, Betainterferon 22mcg
was the only drug with decrement in the period, decreasing from 34,774,157BRL in
2007 to 32,304,159BRL in 2009. CONCLUSIONS:Our findings highlighted geographic
discrepancies within the Brazilian healthcare system in terms of MS treatment
funding even when demographic aspects were considered. Nevertheless a con-
stant increasing in public expenditures was observed across most states.
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OBJECTIVES: To describe inpatient resource use among multiple sclerosis (MS)
patients within the Brazilian public healthcare system (BPHS). METHODS: Inpa-
tient admissions were obtained from the Brazilian Hospital Information System
Database for the period 2006-2009. Records were included if an ICD-10 code G35
(MS) appeared as primary or secondary reason for hospitalization. The following
variables were collected: procedure code for the inpatient admission (relapseman-
agement versus other indications), mean length of stay, mean Intensive Care Unit
(ICU) days, in-hospital mortality, mean cost per hospitalization. Hospitalization
rates were calculated using the estimated MS population under treatment in the
BPHS (estimated from pharmacy claims). Relapse-related admissions were sepa-
rately analyzed. RESULTS: Annual hospitalizations due to MS were 2,142 in 2006,
2,268 in 2007, 1,648 in 2008, and 1,689 in 2009. The hospitalization rates among MS
patients attending BPHS facilities decreased from 0.60 in 2006 to 0.28 in 2009.
Among all admissions, 91.7%were relapse-related in 2006with similar proportions
in 2007 and 2008, and a slightly decrement in 2009 (88.0%). The in-hospital mortal-
ity rate is generally low, with the highest value in 2008 (3.09%) and the lowest in
2009 (1.6%). There were no differences between relapse-related and non-relapse-
related admissions in terms of in-hospital mortality. The mean length of stay was
8.9 days for all MS-related hospitalizations and 7.7 days for those to manage MS.
ICU claims were rare in this sample. In 2009, the observed average cost per hospi-
talization was 675 BRL and the total expenditure with MS inpatient admission was
1,140,418BRL (corresponding to 0.53% of pharmaceutical expenditures due to MS).
CONCLUSIONS:Relapses are responsible for over 90%of all inpatient admissions of
MS patients. Although higher health resource consumption is expected in the out-
patient setting, therapeutic strategies directed at reducing the incidence of re-
lapses can potentially lead to savings within the BPHS.
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OBJECTIVES: This study aimed to investigate the patterns ofmedication treatment
among patients with Multiple Sclerosis (MS) treated in the Brazilian Public Health-
care System (BPHS) and examine possible temporal and spatial trends in those
patterns. METHODS: The study was a longitudinal analysis of Brazilian MS phar-
macy claims as reported in the Brazilian Ambulatory Information SystemDatabase
for the period 2006-2009. Five different drugs currently recommended at BPHS MS
guidelines were included in the analysis (Glatiramer 20mg, Betainterferon 22mcg,
Betainterferon 44mcg, Betainterferon 30mcg, Betainterferon 300mcg) and the pro-
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